Leflunomide Eg

Leflunomide, the active ingredient in Leflunomide Eg, is an immunomodulator presented as an oral tablet for systemic use. It is classified as a disease‑modifying antirheumatic drug (DMARD) and is prescribed to manage rheumatoid arthritis and psoriatic arthritis in adult patients.

GNH USA supplies Leflunomide Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and offers reliable global distribution to meet the needs of healthcare providers.

Leflunomide is a disease‑modifying antirheumatic drug (DMARD) that interferes with the immune system to control chronic inflammatory joint disorders, providing long‑term disease control. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriatic arthritis: alleviates skin and joint symptoms and helps prevent structural damage. - Juvenile idiopathic arthritis (age ≥ 2 years): helps control joint inflammation in pediatric patients. - Adult onset Still’s disease: may improve systemic symptoms and joint involvement. - Systemic lupus erythematosus (off‑label): occasionally used to manage refractory arthritis manifestations.

Leflunomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea: mild to moderate gastrointestinal upset. - Nausea: feeling of sickness or urge to vomit. - Elevated liver enzymes: increased ALT/AST indicating hepatic stress. - Headache: occasional mild to moderate head pain.

Serious or Rare Side Effects: - Severe liver injury: hepatitis or hepatic failure requiring monitoring. - Bone marrow suppression: anemia, leukopenia, or thrombocytopenia. - Pulmonary toxicity: interstitial lung disease or pneumonitis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Leflunomide, clinicians should consider several safety precautions to minimize risks. - Pregnancy: avoid use; teratogenic risk requires effective contraception. - Liver function: assess baseline enzymes and monitor regularly. - Hematology: perform complete blood count before treatment and during therapy. - Infections: screen for latent tuberculosis and monitor for opportunistic infections. - Renal impairment: adjust use cautiously in severe renal dysfunction. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture.

Leflunomide can interact with other medicines, altering its efficacy or increasing toxicity.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, may raise INR. - Methotrexate: additive hepatotoxicity risk. - Rifampin: induces metabolism, reducing Leflunomide levels.

Moderate Interactions (Monitor Closely): - Azathioprine: combined bone marrow suppression. - TNF‑α inhibitors: potential for enhanced immunosuppression. - Simvastatin: may increase statin plasma concentrations.